Established in 1976 by research pioneer Dr. Louis Lasagna, the Tufts Center for the Study of Drug Development (Tufts CSDD) at Tufts University, is an independent, academic, non-profit research group that assesses the nature and pace of pharmaceutical and biopharmaceutical innovation.
Since 1976, Tufts CSDD’s multidisciplinary research staff has undertaken path-breaking research that has influenced industrial R&D strategy and public policy affecting the development and regulation of new medicines. For example:
- Tufts CSDD was the first to determine the cost of developing a new prescription medicine, widely referenced by the U.S. Congress, drug developers, and analysts worldwide. We recently reported that the cost to develop a new biopharmaceutical product is $1.2 billion (in 2005 dollars).
- Early on, Tufts CSDD was the first to document the existence of a significant drug lag between the United States and the United Kingdom. That study, which conclusively demonstrated the link between regulatory policy and innovation, shaped policy debates on the role of the FDA for more than 20 years.
- Tufts CSDD developed the first assessment of the state of the investigator landscape in the U.S., and evaluated the role of cost effectiveness in formulary and clinical practice guidelines in the U.S. and Europe.
- Tufts CSDD recently assessed the therapeutic impact of incremental innovation, sometimes referred to as me-too drug development, and documented the dramatic decline in effective market life for first-in-class pharmaceutical products.